# Tazemetostat Expanded Access Program for Adults With Solid Tumors

> **NCT03874455** · — · NO_LONGER_AVAILABLE · sponsor: **Epizyme, Inc.**

## Conditions studied

- Epithelioid Sarcoma (Ex-US Only)
- Spindle Cell Sarcoma
- Sinonasal Carcinoma
- Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Thoracic Sarcoma
- Poorly Differentiated Chordoma
- ATRT
- Malignant Rhabdoid Tumor of Kidney
- Malignant Rhabdoid Tumor of Ovary
- Malignant Rhabdoid Tumor
- Myxoid Spindle Cell Sarcoma
- Epithelioid Malignant Peripheral Nerve Sheath Tumor
- Chondrosarcoma
- Renal Cell Carcinoma
- Myoepithelial Carcinoma
- Synovial Sarcoma
- Renal Medullary Carcinoma
- Malignant Mesothelioma
- Desmoplastic Small Round Cell Tumor (DSRCT)
- Intramedullary Spinal Cord Schwannomatosis

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT03874455
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874455, "Tazemetostat Expanded Access Program for Adults With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03874455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*